Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 2/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 12/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091652 | 0.91 | SERPINE1 (0.54) | SERPINE1PLA2G2APPARGP2RY14PTGES2 | |
| SCHEMBL6090325 | 0.89 | PPARG (0.42) | SERPINE1PLA2G2APPARGABCB1P2RY14 | |
| SCHEMBL6093040 | 0.84 | SERPINE1 (0.45) | SERPINE1PLA2G2APPARGABCB1P2RY14 | |
| SCHEMBL5777724 | 0.84 | SERPINE1 (0.45) | SERPINE1PLA2G2APPARGP2RY14PTGES2 | |
| SCHEMBL6089976 | 0.82 | PTGES (0.44) | PLA2G2APPARGABCB1PTGES2 | |
| SCHEMBL6092260 | 0.80 | SERPINE1 (0.43) | SERPINE1PLA2G2APPARGP2RY14 | |
| SCHEMBL6091169 | 0.78 | ALDH1A1 (0.46) | SERPINE1PLA2G2APPARG | |
| SCHEMBL6091490 | 0.77 | TP53 (0.47) | PLA2G2AABCB1 | |
| SCHEMBL5749488 | 0.76 | PTGER4 (0.46) | SERPINE1PLA2G2APPARGABCB1P2RY14 | |
| SCHEMBL6091451 | 0.76 | SLC2A1 (0.44) | PLA2G2APPARGABCB1P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | IDO1, PTGS1, IDO2 | SERPINE1 508/4885PLA2G2A 982/4885PPARG 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.